Syndax Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $3,500 | $0 | $536 | $0 |
Gross Profit | -40,837 | -3 | 268 | -3 |
EBITDA | -74,213 | -79,511 | -72,407 | -56,355 |
EBIT | -74,216 | -79,514 | -72,410 | -56,358 |
Net Income | -68,063 | -72,400 | -72,473 | -51,146 |
Net Change In Cash | 3,500 | 0 | 536 | 0 |
Free Cash Flow | -71,645 | -83,548 | -41,349 | -44,653 |
Cash | 105,396 | 114,615 | 295,394 | 94,550 |
Basic Shares | 85,274 | 85,213 | 72,520 | 69,855 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $126,576 | $139,709 | $1,517 |
Gross Profit | -12 | -454 | 139,709 | 1,517 |
EBITDA | -229,942 | -151,724 | 26,263 | -71,334 |
EBIT | -229,954 | -151,757 | 26,220 | -71,423 |
Net Income | -209,360 | -143,749 | 24,926 | -73,069 |
Net Change In Cash | 0 | 126,576 | 139,709 | 1,517 |
Cost of Revenue | 106,722 | 90,634 | ||
Free Cash Flow | -160,601 | -133,900 | 29,002 | -71,260 |
Cash | 295,394 | 74,356 | 221,965 | 115,243 |
Basic Shares | 70,370 | 60,760 | 53,622 | 41,308 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.80 |
2024-03-31 | -$0.85 |
2023-12-31 | -$1 |
2023-09-30 | -$0.73 |
